Spots Global Cancer Trial Database for Efficacy of Tazarotene in Treatment of Verruca Plana

Study Description

Brief Summary: Verruca plana is a common skin infection with worldwide distribution. Approximately 10% of general population is infected with flat warts and it represents up to 18 % of the patients seeking treatment for warts. Verruca plana is not merely an infectious disease but also affects the quality of patients' life. Verruca plana causes major cosmetic and social concerns. Lesions' persistence and recurrence cause frustrations and psychological distress which motivate patients to seek different treatment strategies. Verruca plana commonly affects the school aged children which augments its effect on the psychological and social development of children with stigmatization and bullying are great risks. The available treatment strategies neither ensured complete clearance of the disease nor were free of side effects. Frequently used physical removal methods are operator dependent and commonly lead to irritation, local inflammation, scars, dyspigmentation, and disfigurement. In this study we evaluate the efficacy and the safety of tazarotene gel 0.1% in the treatment of verruca plana compared to imiquimod or 5-fluorouracil

Detailed Description: Patients will be assigned randomly into one of 4 groups as 1:1:1:1 using randomization.com with the seed number 7607 * Group (A): Patients will be treated with topical tazarotene gel 0.1%with a cotton tipped applicator on every lesion once daily at night. * Group (B): Patients will be treated with topical 5- fluorouracil 5% cream applied once daily at night. * Group (C): Patients will be treated with imiquimod cream 5% applied once daily at night. * Group (D): Patients will be treated with petroleum jelly once daily at night.

Keywords

Eligibility

Minimum Age: 4 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial